Posted by Michael Wonder on 02 Nov 2024
Handok's rare blood disorder treatment Empaveli wins insurance coverage
1 November 2024 - Starting today, Handok's Empaveli (pegcetacoplan), a treatment for paroxysmal nocturnal haemoglobinuria, will be covered by Korean health insurance.
Developed by Swedish Orphan Biovitrum (Sobi) and Apellis Pharmaceuticals,Empaveli is the first C3-targeted therapy designed to treat adult PNH patients by addressing both intravascular and extravascular haemolysis.
